Therapeutic area
Gastroenterology and liver
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
12
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
14
Industry-sponsored
Recruiting Phase 3
17
Industry-sponsored
Recruiting Phase 4 (post-approval)
2
Industry-sponsored
Recent approvals
- Lyrfigtu (Lirafugratinib Hydrochloride) · Elevar NovelPriority reviewOrphanSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Rasonque (Daraxonrasib) · Revolution Medicines NovelPriority reviewOrphanAug 26, 2026
To treat metastatic pancreatic cancer
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V. Breakthrough therapyPriority reviewOrphanMay 8, 2026
- Lynavoy (Linerixibat) · Intercept NovelOrphanMar 17, 2026
To treat cholestatic pruritus associated with primary biliary cholangitis
- Nereus (Tradipitant) · Vanda Pharms INC NovelDec 30, 2025
To treat vomiting associated with motion
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V. NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 4, 2024
To treat non-small cell lung cancer and pancreatic adenocarcinoma
- Ziihera (Zanidatamab-Hrii) · Jazz Pharms NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 20, 2024
To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
- Vyloy (Zolbetuximab-Clzb) · Astellas NovelPriority reviewOrphanOct 18, 2024
To treat gastric or gastroesophageal junction adenocarcinoma
- Livdelzi (Seladelpar Lysine) · Gilead Sciences INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanAug 14, 2024
To treat primary biliary cholangitis (PBC)
- Iqirvo (Elafibranor) · Ipsen NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanJun 10, 2024
To treat primary biliary cholangitis in combination with ursodeoxycholic acid
- Rezdiffra (Resmetirom) · Madrigal NovelBreakthrough therapyAccelerated approvalPriority reviewMar 14, 2024
To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
- Tevimbra (Tislelizumab-Jsgr) · Beigene NovelOrphanMar 13, 2024
To treat unresectable or metastatic esophageal squamous cell carcinoma
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
Largest recruiting Phase 3 trials
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06528314 · 2,150 participants (planned) · Start Oct 4, 2024 · Primary completion Feb 2030
Drug: Efruxifermin; Placebo · For: NASH - Nonalcoholic Steatohepatitis; MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 359 sites in all
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06419374 · 1,800 participants (planned) · Start May 24, 2024 · Primary completion Jun 30, 2028
Drug: Pegozafermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Sites: Birmingham, Alabama; Homewood, Alabama; Chandler, Arizona · 335 sites in all
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06215716 · 1,650 participants (planned) · Start Dec 1, 2023 · Primary completion Feb 2033
Drug: Efruxifermin; Placebo · For: NASH With Fibrosis; MASH With Fibrosis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 361 sites in all
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07854782 · 1,500 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 3, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD
Sites: Miami, Florida; Marrero, Louisiana; Metairie, Louisiana · 5 sites in all
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06318169 · 1,350 participants (planned) · Start Mar 13, 2024 · Primary completion Feb 2029
Drug: Pegozafermin · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Sites: Birmingham, Alabama; Chandler, Arizona; Flagstaff, Arizona · 370 sites in all
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221188 · 1,250 participants (planned) · Start Dec 12, 2025 · Primary completion Mar 24, 2028
Drug: Efimosfermin Alfa; Placebo · For: Non-alcoholic Fatty Liver Disease
Sites: Arcadia, California; Covina, California; Los Angeles, California · 66 sites in all
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221227 · 1,200 participants (planned) · Start Oct 24, 2025 · Primary completion Mar 29, 2028
Drug: Efimosfermin alfa; Efimosfermin alfa and 1 more · For: Non-alcoholic Fatty Liver Disease
Sites: Chandler, Arizona; Tucson, Arizona; Little Rock, Arkansas · 91 sites in all
- A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASHPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07581951 · 886 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2029
Drug: HSK31679; Placebo · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH (Non-Alcoholic Steatohepatitis)
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 WeeksPivotal-lookingRecruiting
Phathom Pharmaceuticals, Inc.Industry
NCT07752407 · 500 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 20, 2027
Drug: Vonoprazan; Placebo · For: Symptomatic Non-erosive Gastroesophageal Reflux Disease
Sites: Mentor, Ohio
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.